Changes in Beneficial Ownership · 4
EyePoint, Inc.
EYPTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primarydocument.xml
Filing details
- Report period
- 2026-08-18
- Issuer
- EyePoint, Inc.
- Issuer CIK
- 0001314102
- Trading symbol
- EYPT
Reporting owner 1
- Name
- Zaderej Karen L.
- Reporting owner CIK
- 0001530968
- Relationship
- Director
- Address
- C/O EYEPOINT, INC., 480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-18 | P · Form 4 | 10,600.00 | A | 4.93 | 49,100.00 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Signature 1
- Signed
- /s/ Ron Honig, Attorney-in-Fact
- Date
- 2026-08-18
Company context
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Nov 4, 2026
- SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
- Other EventsOct 19, 2026
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Oct 7, 2026